- Home
- ET vs TAK Comparison
ET vs TAK Comparison
Compare ET & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ET | TAK |
|---|---|---|
| Founded | 2002 | 1781 |
| Country | United States | Japan |
| Employees | 22311 | 47455 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5B | 56.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ET | TAK |
|---|---|---|
| Price | $18.87 | $18.77 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $21.67 | N/A |
| AVG Volume (30 Days) | ★ 13.8M | 2.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.94% | 2.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.75 | $0.04 |
| Revenue Next Year | $4.39 | $0.92 |
| P/E Ratio | ★ $15.59 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.60 | $12.99 |
| 52 Week High | $19.86 | $18.82 |
Technical Indicators
Market Signals| Indicator | ET | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 62.00 |
| Support Level | $18.29 | $17.65 |
| Resistance Level | $19.26 | N/A |
| Average True Range (ATR) | 0.36 | 0.26 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 28.57 | 88.74 |
Price Performance
Historical ComparisonAbout ET Energy Transfer LP
Energy Transfer is a diversified midstream firm, operating from wellhead to consuming demand. It handles natural gas, natural gas liquids, or NGLs, crude oil, and refined products. Commodities are moved through its network of field level gathering and processing to refineries and demand centers. Operations are concentrated in Texas and the Midcontinent United States. It also controls Sunoco and USA Compression through its general partner relationship.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.